

| Knowledge across
the borders



Refbio, the reference in biomedical research of the Pyrenean community

Refbio is a **trans-Pyrenean cooperation network for biomedical** research, started in 2012 and involving today 9 institutions from 6 regions on both sides of the Pyrenees.

Its main objective is to **promote cross-border cooperation between Spain and France** for research of excellence at a European level in areas such as oncology, haematology, cell therapy, neuroscience, epidemiology and public health, cardiovascular and infectious diseases, and clinical trials.

Between 2012 and 2015, the first **Refbio** phase settled the collaboration between the regions and resulted in 17 scientific projects, 4 specialized workshops and 2 summer schools.

In total, approximately 2,100 research and management of health professionals were involved.

In 2016, the second phase of **Refbio** (2016-2018) was launched in order to consolidate the network and improve effective transfer of biomedical R&D results and their valuation in the Pyrenean area.

In this second phase, the following objectives have been set:

- Intensify **collaboration with representatives of the specialized biomedical sector in innovation.**
- Stimulate **innovation and technology transfer.**
- Make effective use of **R&D** results obtained thanks to public-private cooperation

During the **30 months of work**, **Refbio II** has planned the organization 2 calls for the implementation of cross-border research projects between the different partners with the collaboration of companies.

Network Priority Research Fields:

- Health sectors ICTs
- Drugs and clinical trials
- Technology platforms
- Therapeutic trials for chronic diseases
- Normal and pathological ageing.

The European Regional Development Fund (ERDF) is co-financing 65% of the project within the framework of the Interreg V-A Spain-France-Andorra Program (POCTEFA 2014-2020). The objective of the POCTEFA is to strengthen the economic and social integration of the Spain-France-Andorra border area. Its assistance focuses on the development of cross-border economic, social, and environmental activities through joint strategies for sustainable territorial development.

Refbio II, collaborative research projects

EPICHRONIC II

Impact of new antidiabetic drugs on the treatment of Type 2 Diabetes and patients' safety: a pharmacoepidemiological challenge.

Topic: Chronic Diseases

Partners: Université Paul Sabatier, CHUT, IACS,
Navarrabiomed-FMS, BIOEF

Project leader: Maryse Lapeyre-Mestre • Université Paul Sabatier

HEADLINE

Link between cardiovascular and neurodegenerative diseases through the focus of epigenetic changes in the RNA.

Topic: Neurosciences

Partners: CHUT, Biocruces

Project leader: Anne Pavy-Letraon • CHUT

HEPATIC

HMB for undernutrition on patients with cirrhosis.

Topic: Clinical Trials

Partners: IACS, Université Paul Sabatier, Rioja Salud-CIBIR,
Biocruces

Project leader: José Miguel Arbones Mainar • IACS

IGOR

IGF1, an option for regenerative medicine.

- Topic: Regenerative medicine
- Partners: Université Paul Sabatier, IACS, Rioja Salud-CIBIR
- Project leader: Jean-Michel Senard • Université Paul Sabatier

MOL_CRC

New biomarkers with potential clinical value in the consensus of molecular subtypes of colorectal cancer.

- Topic: Oncology
- Partners: Navarrabiomed-FMS, CHUT, Rioja Salud-CIBIR
- Project leader: Maria Luisa Gómez Dorronsoro • Navarrabiomed-FMS

MOMENEU

Identification of common molecular mechanisms in neurodegeneration.

- Topic: Neurosciences
- Partners: Rioja Salud-CIBIR, Navarrabiomed-FMS, Université Paul Sabatier, Biocruces, IACS
- Project leader: Juan Cabello • Rioja Salud-CIBIR

PROBIOMEL

Research and validation of prognostic biomarkers for melanoma.

- Topic: Oncology
- Partners: Rioja Salud-CIBIR, Navarrabiomed-FMS, Université Paul Sabatier
- Project leader: Ignacio Larráyoiz • Rioja Salud-CIBIR

Refbio II, R&D innovation projects and transfer

IKERIKTUS

Validation of biomarkers associated with instability in atherosclerosis-carotid disease.

■ Topic: Neurosciences

Partners: BIOEF

Project leader: Maria del Mar Freijo Guerrero • BIOEF

IBD-IFXADA

New tools for optimizing Infliximab or Adalimumab treatments in patients with inflammatory bowel disease.

■ Topic: Inflammatory & Infectious Diseases / Immunology

Partners: BIOEF, Biocruces

Project leader: Maria del Carmen Muñoz • BIOEF

SAT-PREDIAB

Development and validation of an alarm system for the detection of adverse events in patients with hyperglycaemia based on predictive modelling.

■ Topic: Health Technologies

Partners: BIOEF, IACS, Biodonostia

Project leader: Urko Aguirre • BIOEF

3D3B

Printing the brain: Towards a 3D-Bioprinted model of human blood-brain barrier..

Topic: Neurosciences

Partners: Navarrabiomed-FMS

Project leader: Natalia Ramirez • Navarrabiomed-FMS

BMK_PANC

Multi-institutional study on the definition of new predictive biomarkers of response in resectable pancreatic adenocarcinoma, with poor prognostic factors, treated with neoadjuvants. Serum pharmacoproteomic correlation of response to treatment.

Development of a prognostic/predictive biosensor from this experience.

Topic: Oncology

Partners: Navarrabiomed-FMS, Biodonostia, CHUT, IACS

Project leader: Antonio Viudez • Navarrabiomed-FMS

MEMOSHIELD

Proof of concept of a new medication that prevents age-related memory loss.

Topic: Neurosciences

Partners: Rioja Salud-CIBIR, Biodonostia, IACS

Project leader: Alfredo Martínez Ramírez • Rioja Salud-CIBIR

BLT-CEL

Impact of circulating tumour cells on plasma serum by differential scanning calorimetry (DSC) analysis: Thermal Liquid Biopsy and its application in clinical diagnosis.

Topic: Oncology

Partners: IACS

Project leader: Olga Abian Franco • IACS

Refbio II, R&D innovation projects and transfer

LACTODERMAL

Extraction of exosomes from milk and their use in skin regeneration.

- Topic: Stem Cells & Therapeutic Innovation
- Partners: IACS, Biodonostia
- Project leader: María Pilar Martín Duque • IACS

AGE-HDACIS

Preclinical study of a new compound to improve tissue regeneration and delay aging.

- Topic: Stem Cells & Therapeutic Innovation
- Partners: Biodonostia, Rioja Salud-CIBIR, Université Paul Sabatier
- Project leader: Ander Matheu • Biodonostia

ANGIOMIMETICS

Development of applications in microfluidic chips for the evaluation of pharmacological demodulators of angiogenesis.

- Topic: Oncology
- Partners: IACS
- Project leader: Angel García Otín • IACS

GEOSIGEPOC-ASMA

Integration of cartographic tools and spatial perspective in the Health Information Systems of the Aragonese Health

Service: Design and application to the pilot study of the prevalence of COPD and Asthma in the Autonomous Community of Aragon.

Topic: Health Technologies and Innovations

Partners: IACS

Project leader: Marcos Zuñil Martín • IACS

DATAANAERC

«Data Analytics» from injury to kidney repair in patients with chronic kidney disease (CKD).

Topic: Health Technologies. Stem Cells & Therapeutic Innovations

Partners: Biodonostia, CHUT

Project leader: Marcos Araúz Bravo • Biodonostia

ELIFRAIL

Nutritional status and its relationship to functional capacity on elder people: an opportunity for the development of innovative interventions for the prevention and treatment of fragility and dependence.

Topic: Health Innovation

Partners: Biodonostia, Cluster Osasuna

Project leader: Itziar Vergara • Biodonostia



Refbio II 2016 2018

PYRENEES BIOMEDICAL NETWORK



CONTACTS

More information about the project
media@refbio.eu • info@refbio.eu
www.refbio.eu



Programme financé par le FEDER